Sugars and cell adhesion: the role of ST6GalNAc1 in prostate cancer progression by Munkley J & Elliott DJ
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Munkley J, Elliott DJ. Sugars and cell adhesion: the role of ST6GalNAc1 in 
prostate cancer progression. Cancer Cell & Microenvironment 2016, 3(1): 
e1174. 
 
 
Copyright: 
© 2016 The Authors. Licensed under a Creative Commons Attribution 4.0 International License which 
allows users including authors of articles to copy and redistribute the material in any medium or format, 
in addition to remix, transform, and build upon the material for any purpose, even commercially, as long 
as the author and original source are properly cited or credited. 
DOI link to article: 
http://dx.doi.org/10.14800/ccm.1174  
Date deposited:   
19/02/2016 
  
Cancer Cell & Microenvironment 2016; 3: e1174. doi: 10.14800/ccm.1174; © 2016 by Jennifer Munkley, et al. 
http://www.smartscitech.com/index.php/ccm 
 
Page 1 of 4 
 
 
 
 
Sugars and cell adhesion: the role of ST6GalNAc1 in prostate 
cancer progression 
 
Jennifer Munkley, David J. Elliott 
 
Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne NE1 3BZ, UK 
 
Correspondence: Jennifer Munkley 
E-mail: Jennifer.munkley@ncl.ac.uk 
Received: December 29, 2015 
Published online: February 08, 2016 
 
 
O-linked glycans become altered in cancer cells, leading to changes in cell adhesive properties and contributing 
to metastasis. But the mechanisms driving these changes and how these carbohydrate groups are involved in 
tumour spread remain poorly understood. We recently identified the sialyltransferase gene ST6GalNAc1 as a 
novel androgen-regulated gene in prostate cancer [1]. Expression of ST6GalNAc1 in prostate cancer cells induced 
expression of the cancer-associated sTn antigen, reduced cell adhesion, and dramatically inhibited the formation 
of stable tumour masses in vivo after orthotopic transplantation experiments in mice. Although ST6GalNAc1 is 
significantly upregulated in primary prostate carcinoma tissue, there is a striking downregulation of this gene in 
metastatic prostate tissue, suggesting an important yet transient role for ST6GalNAc1 in prostate cancer 
progression. Here we discuss mechanistically how changes in sialylation could alter prostate tumour cell 
behaviour and contribute to cancer cell dissemination.  
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Metastasis remains the principal cause of mortality from 
solid tumours. There is a key clinical need to develop 
biomarkers indicative of metastatic disease to help stratify 
patients towards personalised therapy. Cancer cell 
dissemination from the primary site and establishment at a 
secondary site occurs through a complex multistep process. 
Key questions are how tumour cells within the primary tumour 
overcome the cell-cell adhesion forces which normally hold 
tissue in place, and then reattach themselves at a new site. 
Alterations in cell surface glycosylation are closely linked 
with the malignant properties of cancer cells. Cell surface 
glycans can alter cell-cell and cell-matrix adhesion and can 
alter adhesive properties leading to tumour spread. Studies 
strongly suggest that truncation of O-glycans directly induces 
oncogenic features of growth and invasion [2, 3]. The most 
frequently observed aberrant glycophenotype is expression of 
the most immature truncated O-glycans Tn and sTn [2, 3]. 
However, the mechanisms driving the expression of these 
glycans and they are involved in tumour spread remain poorly 
understood. 
Mucin (GalNAc) -type O-glycosylation of proteins is an 
abundant and diverse form of post-translational modification 
that is initiated by a family of enzymes called GalNAc-
transferases. These enzymes modify proteins by transferring 
GalNAc residues, and in subsequent steps these GalNac 
residues are further elongated, branched and capped to result 
in O-glycosylation. Whereas in normal cells O-glycosylation 
produces mature elongated and branced O-glycans capped by 
sialic acid, many cancer cells express 
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only biosynthetic intermediates [3, 4]. Although the mechanism 
and biological significance of the truncated O-glycophenotype 
remains to be widely addressed, the expression of truncated 
O-glycans in cancer is thought to result from several different 
mechanisms, including altered expression, localisation or 
topology of glycosyltransferases [5-8], and fluctuations in 
cellular pH [9, 10]. O-glycosylation is an abundant protein 
modification; More than 80% of the human proteome that 
enters and passes through the secretory apparatus is predicted 
to be O-glycosylated [11]. The site-specific O-glycosylation of 
proteins can have a dramatic effect on protein function, 
including pro-protein processing, modulation of ligand 
binding and regulation of cell signalling [12-15]. 
We recently showed that expression of the sialytransferase 
ST6GalNAc1 is directly regulated by androgens in prostate 
cancer cells, and its encoding gene is upregulated in primary 
prostate cancer tissue relative to the normal prostate gland [1]. 
ST6GalNAc1 protein is responsible for catalysing synthesis of 
the truncated cancer-associated sialyl-Tn antigen (sTn) which 
is elevated in several cancer types and correlates with 
metastasis and poor prognosis in breast and colon cancer [16-
23]. In prostate cancer, the sTn antigen is detected in up to half 
of high grade prostate carcinomas [16, 24], and the levels of sTn 
MUC1 have been correlated with worse survival outcomes 
and higher serum PSA levels in prostate cancer patients [25]. 
Androgen steroid hormones are key molecular drivers in 
prostate cancer, and our recent study showing that sTn 
expression is induced by androgens in prostate cancer cells, 
provides a link between the androgen receptor and expression 
of this cancer-associated antigen. 
The truncation of O-glycans has previously been reported 
to play a role in cell invasion through the disruption of contact 
between the epithelium and the dermal compartment and loss 
of cell-cell adhesion [2]. To establish the role of ST6GalNAc1 
in prostate cancer we used engineered DU145 and PC3 cells, 
which normally express low endogenous levels of 
ST6GalNAc1, to overexpress this sialytransferase and 
demonstrate that this induces expression of the sTn antigen in 
prostate cancer cells [1]. Prostate cancer cells expressing 
ST6GalNAc1 and sTn antigen have reduced cell adhesion 
onto uncoated plates and plates coated with collagen I or 
fibronectin, increased cell motility, and switch towards a more 
mesenchymal cell phenotype. The increased expression of 
sialylated antigens can create negative charges which can 
promote the detachment of cells from the tumour mass through 
electrostatic repulsion. Consistent with this, prostate cancer 
Figure 1. Model: ST6GalNAc1 inhibits the formation of solid tumours in prostate cancer cells. 
Prostate cancer cells with low ST6GalNAc1 do not express the sTn antigen and are able to form solid 
tumours in vivo. In contrast, in prostate cancer cells expressing the ST6GalNAc1 enzyme there is an 
induction of the sTn antigen, a reduction of E-cadherin expression, reduced cell adhesion, and the 
cells are unable to form solid tumours. 
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cells expressing ST6GalNAc1 and the sTn-antigen are unable 
to form stable tumour masses in vivo within orthotopically 
transplanted mice, thus suggesting a role for ST6GalNAc1 in 
prostate cancer cell dissemination (Figure 1).  
A recent study used quantitative phospho-proteomics to 
examine the main signalling pathways affected by truncation 
of O-glycans in pancreatic cancer cells [2]. The analysis 
revealed altered regulation of proteins involved in cell 
adhesion [2]. Similarly, we found that prostate cancer cells 
expressing ST6GalNAc1 have decreased expression of the 
epithelial cell-cell adhesion molecule E-cadherin and 
increased expression of migration-associated N-cadherin and 
vimentin proteins [1]. The epithelial to mesenchymal (EMT) 
transition has a role in the progression of prostate cancer [26-
29]. A switch from E-cadherin to N-cadherin expression is of 
strong independent importance for the progress of prostate 
cancer [26-29], and up-regulation of vimentin expression is 
linked to prostate cancer invasion [29]. Our findings add to the 
growing evidence linking glycosylation and the EMT 
transition [30-33], and provide important insight into 
understanding how O-linked glycans can influence this 
process. Further dissection of the interplay between sTn and 
oncogenic features will require deciphering the effects of sTn 
on additional specific O-glycoproteins.  
Alterations in O-glycans in cancer can alter ligands 
responsible for interactions between cancer cells and their 
environment and have many biological and pathological 
consequences. This can influence the growth and survival of 
cancer cells, the ability to metastasise, and interactions with 
cell surface receptors, lectins, and cells of the immune system. 
The patterns of ST6GalNAc1 expression in prostate cancer are 
consistent with a potentially transient role for ST6GalNAc1 in 
prostate cancer progression: the ST6GalNAc1 gene is up-
regulated in primary prostate cancer tissue, but then strikingly 
down-regulated in metastatic prostate tissue relative to the 
normal prostate gland [1]. While ST6GalNAc1 protein could 
have a role in facilitating dissemination from the primary 
tumour, these dynamic gene expression patterns suggest that 
ST6GalNAc1 must subsequently be lost in order to form stable 
metastases.  
Our findings in prostate cancer are in contrast to studies in 
breast and colon cancer cells where the ST6GalNAc1 enzyme 
was found to be increased in metastatic tissue and to increase 
primary tumour growth and the formation of metastatic foci 
[20, 23]. This suggests that the roles of ST6GalNAc1 will need 
to be analysed individually in different cancers. The 
differences in ST6GalNAc1 function observed between 
breast/colon and prostate cancer could be due to differences in 
cellular background or due the influence of other co-expressed 
glycosylation enzymes. In future studies it will be important 
to understand how changes in glycodynamics function co-
ordinately to influence specific stages of cancer progression. 
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